{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015705","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.815965+00:00","generated_at":"2026-05-30T00:34:53.532714+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics reports Q3 net loss of $0.17/share; plans Phase 1b start for GT-02287 by year-end","bullets":["Net loss per share improved to $0.17 from $0.37 in Q3 2023; R&D spend rose to $2.6M.","Cash and marketable securities $12M as of Sept 30, 2024, down from $16.8M at Dec 31, 2023.","Phase 1 MAD results showed 53% increase in GCase activity; safety and tolerability confirmed.","Initiation of Phase 1b trial in Parkinson's patients expected by end of Q4 2024.","Pre-IND meeting with FDA planned before end of 2024 to support Phase 2 expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015705","json":"https://secwatch.observer/filing/0001558370-24-015705.json","markdown":"https://secwatch.observer/filing/0001558370-24-015705.md","text":"https://secwatch.observer/filing/0001558370-24-015705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024015705/0001558370-24-015705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024015705/ganx-20241114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:34:53.532714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}